Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.

The goal of this observational study is to evaluate the safety and clinical benefit of two doses of CYFENDUS vaccine when used with the concurrent recommended antibacterial regimen for post-exposure prophylaxis to prevent inhalational anthrax and/or anthrax meningitis.

NCT Number	NCT07268612
Lead Sponsor	Emergent BioSolutions
Conditions	Anthrax
Enrollment	250 participants
Start Date	2035-11
Primary Completion	2036-11 (estimated)
Study Completion	2037-11 (estimated)
Updated on ClinicalTrials.gov	2025-12-08